In second-line or later therapy, HER2-positive patients exhibited superior ORR versus HER2-low subgroups (39%, 95% CI: 30%–47% vs. 25%, 95% CI: 11%–39%) (Figure 3B), while tumor location did not significantly influence outcomes (Figure 3C). The gene discussed is ERBB2; the disease is neoplasm.